Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes

Swati Pabreja, Tarun Garg, Goutam Rath, Amit K. Goyal

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Tuberculosis (TB) is one of the major devastating diseases in the world, mainly caused by Mycobacterium tuberculosis. Furthermore, multi-drug resistant TB and extremely drug resistant TB are becoming big problems globally. Bacillus Calmette-Guerin (BCG) is the only available vaccine which provides protection against TB. The BCG vaccine is effective in children but not recommended in adults and elderly patients due to an associated low risk of infection with Mycobacterium tuberculosis and variable effectiveness of the vaccine. The main aim of this research study is to develop such a vaccine which will provide a better and safer profile in children and adults, as well as in elderly patients. In this present study, we prepared pulmonary tubercular vaccine by using an Antigen 85 complex (Ag85)-loaded nanocarrier such as the immunostimulating complex (ISCOM). Immunological outcomes clearly indicated significant improvement in humoral as well as cellular immune responses after pulmonary immunization with ISCOMs containing Quil A in mice.
Original languageEnglish (US)
Pages (from-to)532-539
Number of pages8
JournalArtificial Cells, Nanomedicine and Biotechnology
Issue number2
StatePublished - Jan 1 2016
Externally publishedYes

Bibliographical note

Generated from Scopus record by KAUST IRTS on 2023-10-12

ASJC Scopus subject areas

  • Biotechnology
  • Biomedical Engineering
  • Pharmaceutical Science
  • Medicine (miscellaneous)


Dive into the research topics of 'Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes'. Together they form a unique fingerprint.

Cite this